Wu Wei-Dong, Fang Chi-Hua, Yang Zheng-Xin
Department of Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jan;28(1):60-4.
To investigate the effect of cationic liposome-mediated RNA interference (RNAi) in silencing epidermal growth factor (EGF) receptor (EGFR) gene in breast cancer cells in vivo.
A small interfering RNA (siRNA) targeting EGFR gene was constructed and transfected into human breast cancer cell in vitro via cationic liposome. The transfected cells were inoculated into nude mice, and the tumor growth inhibition rate was calculated. The tumors were then removed for immunohistochemistry and Western blotting to examine the expression of EGFR protein. Quantitative RT-PCR was used to detect the mRNA expression of the EGF receptor gene, and enzyme-linked immunosorbent assay (ELISA) performed to assess the EGF level in both the serum and tumor extraction.
In athymic nude mice, MDA-MB-231 cells had obviously lower tumor formation rate than ZR-75 cells (30.00% and 88.89%). Transfection of the cells with EGFR siRNA significantly inhibited tumor formation capacity of the cells in vivo as compared with the cells transfected with empty vector or irrelevant siRNA. The results of ELISA demonstrated that in mice bearing the tumors grown from EGFR siRNA-transfected cells, the EGF levels in the serum and tumor extraction were lowered by 16.77% and 12.59%, respectively. Real-time RT-PCR showed that EGFR siRNA transfection caused a specific downregulation of EGFR mRNA expression by 21.05% in the tumor.
Chemically synthesized 21-nucleotide siRNA duplexes can be effectively delivered via lipofectamine 2000 into breast cancer cells in vivo to induce a longer-lasting gene silencing effect than in vitro transfection. RNAi of EGFR gene may indicate a promising approach for management of lung cancers, especially those nodular ones with easy access.
研究阳离子脂质体介导的RNA干扰(RNAi)在体内沉默乳腺癌细胞表皮生长因子(EGF)受体(EGFR)基因的效果。
构建靶向EGFR基因的小干扰RNA(siRNA),通过阳离子脂质体体外转染人乳腺癌细胞。将转染后的细胞接种到裸鼠体内,计算肿瘤生长抑制率。然后取出肿瘤进行免疫组织化学和蛋白质印迹分析,检测EGFR蛋白的表达。采用定量逆转录聚合酶链反应(RT-PCR)检测EGF受体基因的mRNA表达,并进行酶联免疫吸附测定(ELISA)评估血清和肿瘤提取物中的EGF水平。
在无胸腺裸鼠中,MDA-MB-231细胞的肿瘤形成率明显低于ZR-75细胞(30.00%和88.89%)。与转染空载体或无关siRNA的细胞相比,用EGFR siRNA转染细胞显著抑制了其在体内的肿瘤形成能力。ELISA结果表明,在接种由EGFR siRNA转染细胞生长而来肿瘤的小鼠中,血清和肿瘤提取物中的EGF水平分别降低了16.77%和12.59%。实时RT-PCR显示,EGFR siRNA转染使肿瘤中EGFR mRNA表达特异性下调21.05%。
化学合成的21核苷酸siRNA双链体可通过脂质体2000有效递送至体内乳腺癌细胞,诱导比体外转染更持久的基因沉默效果。EGFR基因的RNAi可能是治疗肺癌尤其是那些易于触及的结节性肺癌的一种有前景的方法。